In preclinical models, the inhalation of a mixture of living Lactobacilli bacteria attenuated pulmonary inflammation and improved lung function and structure for the chronic lung diseases ...
Brensocatib, newly approved by the FDA for noncystic fibrosis bronchiectasis (NCFB), was also associated with improvements in lung structure, on the basis of data from a substudy of 100 individuals ...
Researchers at the Institute of Industrial Science, The University of Tokyo have developed a system that allows human lung ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
High levels of phenotypic age acceleration (PhenoAgeAccel) were found to have a more significant effect on lung function in patients with chronic obstructive pulmonary disease (COPD), older patients, ...
In a recent study posted to the bioRxiv preprint server, researchers develop the ‘crystal ribcage,’ a transparent ribcage for real-time lung imaging at cellular resolution. Study: Crystal Ribcage: A ...
Please provide your email address to receive an email when new articles are posted on . Higher levels of a biomarker for propylene oxide signaled worse measures of FVC and FEV 1. This relationship is ...
Dr. Joshua K. Sabari explains how surgery, radiation and therapy may reduce lung capacity and shares steps survivors can take to protect their breathing health. In a recent video interview, Dr. Joshua ...
This study, published in the journal Nature Communications, determined the mechanism of this live biotherapeutic product — a powder mixture of living Lactobacilli bacteria — to reduce neutrophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results